FR22C1025I2 - Analogues de la compstatine à longue durée d'action et compositions et méthodes associées - Google Patents

Analogues de la compstatine à longue durée d'action et compositions et méthodes associées

Info

Publication number: FR22C1025I2
Authority: FR; France
Prior art keywords: methods; long; related compositions; compstatin analogs; acting compstatin
Prior art date: 2012-11-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1025C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Apellis Pharmaceuticals Inc

Original Assignee

Apellis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-15

Filing date

2022-06-08

Publication date

2023-11-24

2022-06-08 Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc

2022-07-22 Publication of FR22C1025I1 publication Critical patent/FR22C1025I1/fr

2023-11-24 Application granted granted Critical

2023-11-24 Publication of FR22C1025I2 publication Critical patent/FR22C1025I2/fr

Status Active legal-status Critical Current

Links

RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Detergent Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FR22C1025C 2012-11-15 2022-06-08 Analogues de la compstatine à longue durée d'action et compositions et méthodes associées Active FR22C1025I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261727094P	2012-11-15	2012-11-15
PCT/US2013/070417 WO2014078731A2 (en)	2012-11-15	2013-11-15	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP13854990.2A EP2920201B1 (en)	2012-11-15	2013-11-15	Long-acting compstatin analogs and related compositions and methods

Publications (2)

Publication Number	Publication Date
FR22C1025I1 FR22C1025I1 (fr)	2022-07-22
FR22C1025I2 true FR22C1025I2 (fr)	2023-11-24

Family

ID=50731833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1025C Active FR22C1025I2 (fr)	2012-11-15	2022-06-08	Analogues de la compstatine à longue durée d'action et compositions et méthodes associées

Country Status (25)

Country	Link
US (4)	US10035822B2 (hu)
EP (3)	EP3929206A1 (hu)
JP (5)	JP2016505527A (hu)
CN (2)	CN105051057B (hu)
AU (4)	AU2013344462B2 (hu)
BR (1)	BR112015011244B1 (hu)
CA (1)	CA2891673A1 (hu)
CY (1)	CY1124474T1 (hu)
DK (2)	DK2920201T3 (hu)
ES (2)	ES2879430T3 (hu)
FR (1)	FR22C1025I2 (hu)
HK (2)	HK1215445A1 (hu)
HR (1)	HRP20211342T2 (hu)
HU (2)	HUE055564T2 (hu)
IL (2)	IL238852A0 (hu)
LT (2)	LT3660033T (hu)
MX (2)	MX366404B (hu)
NL (1)	NL301178I2 (hu)
NO (1)	NO2022017I1 (hu)
PL (2)	PL2920201T3 (hu)
PT (2)	PT2920201T (hu)
RS (1)	RS62243B9 (hu)
SI (1)	SI3660033T1 (hu)
SM (1)	SMT202100514T1 (hu)
WO (1)	WO2014078731A2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2915265T3 (es)	2011-05-11	2022-06-21	Apellis Pharmaceuticals Inc	Análogos de compstatina reactivos con células, de acción prolongada o dirigidos y usos de los mismos
CN105051057B (zh)	2012-11-15	2019-11-19	阿佩利斯制药公司	细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN117503905A (zh)	2015-10-07	2024-02-06	阿佩利斯制药有限公司	给药方案
EP3526328A4 (en) *	2016-10-17	2020-05-27	Apellis Pharmaceuticals, Inc.	COMBINATION THERAPY FOR C3 INHIBITION
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3606465A4 (en)	2017-04-07	2021-03-24	Apellis Pharmaceuticals, Inc.	DOSAGE SCHEDULES AND ASSOCIATED COMPOSITIONS AND PROCESSES
WO2019028284A1 (en)	2017-08-02	2019-02-07	Achillion Pharmaceuticals, Inc.	THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
CN109701030A (zh) *	2017-10-26	2019-05-03	湖南华腾制药有限公司	聚乙二醇化小分子药物的制备方法
MA51162A (fr) *	2017-12-15	2020-10-21	Apellis Pharmaceuticals Inc	Schémas posologiques et compositions et procédés associés
EP3645550B1 (en) *	2018-04-06	2021-11-03	The Trustees Of The University Of Pennsylvania	Compstatin analogs with increased solubility and improved pharmacokinetic properties
WO2020041301A1 (en)	2018-08-20	2020-02-27	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051532A2 (en)	2018-09-06	2020-03-12	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for the treatment of medical disorders
EP3847174A4 (en)	2018-09-06	2022-06-15	Achillion Pharmaceuticals, Inc.	MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
MX2021003425A (es)	2018-09-25	2021-07-16	Achillion Pharmaceuticals Inc	Formas morficas de los inhibidores del factor d del complemento.
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
US11510939B1 (en)	2019-04-19	2022-11-29	Apellis Pharmaceuticals, Inc.	RNAs for complement inhibition
CN110244053B (zh) *	2019-05-09	2022-03-11	北京大学第三医院（北京大学第三临床医学院）	用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
CA3143257A1 (en) *	2019-07-05	2021-01-14	Apellis Pharmaceuticals, Inc.	Viral vector therapy
WO2021011927A1 (en) *	2019-07-18	2021-01-21	Apellis Pharmaceuticals, Inc.	Complement inhibitor dosing regimens
CN111235264B (zh) *	2020-02-20	2023-05-16	圣湘生物科技股份有限公司	检测人tpmt基因和nudt15基因多态性的组合物、试剂盒及方法
WO2021168320A1 (en)	2020-02-20	2021-08-26	Achillion Pharmaceuticals, Inc.	Heteroaryl compounds for treatment of complement factor d mediated disorders
CN111265651A (zh) *	2020-02-29	2020-06-12	华中科技大学同济医学院附属同济医院	补体c3抑制剂cp40-kk在制备防治肺动脉高压病药物中的应用
US20230158063A1 (en) *	2020-04-06	2023-05-25	The Trustees Of Indiana University	Airway epithelial alkaline therapy to treat viral respiratory infection
CN118812653A (zh) *	2023-04-18	2024-10-22	成都奥达生物科技有限公司	一种长效坎普他汀化合物

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2295746A1 (fr)	1974-12-23	1976-07-23	Francaise Coop Pharma	Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
IT1179866B (it)	1984-12-12	1987-09-16	Rotta Research Lab	Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en)	1985-04-22	1986-03-18	Merck & Co., Inc.	Tryptophan derivative
US5157110A (en)	1988-08-20	1992-10-20	The Government Of The United States Of America	Synthetic, anti-complement protein
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
IL95942A0 (en)	1989-10-13	1991-07-18	Syntex Inc	Collagen-containing ophthalmic formulation
US6395888B1 (en)	1996-02-01	2002-05-28	Gilead Sciences, Inc.	High affinity nucleic acid ligands of complement system proteins
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
EP1413587A2 (en)	1991-05-03	2004-04-28	Washington University	Modified complement system regulator
US5492135A (en)	1992-09-09	1996-02-20	Devore; Dale P.	Collagen modulators for use in photoablation excimer laser keratectomy
US5482135A (en)	1993-06-29	1996-01-09	Deere & Company	Combined hydraulic reservoir and vehicle axle
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
WO1995003807A1 (en)	1993-07-27	1995-02-09	The University Of Sydney	Treatment of age-related macular degeneration
US5470952A (en)	1993-10-20	1995-11-28	Regeneron Pharmaceuticals, Inc.	CNTF and IL-6 antagonists
US5443505A (en)	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
US5776970A (en)	1994-04-28	1998-07-07	Yeda Research And Development Co. Ltd.	Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH08280800A (ja)	1995-04-12	1996-10-29	Nissho Corp	２液注射用プレフィルドシリンジ
US5869079A (en)	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129761A (en)	1995-06-07	2000-10-10	Reprogenesis, Inc.	Injectable hydrogel compositions
US6346398B1 (en)	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU2203197A (en)	1996-03-13	1997-10-01	Trustees Of The University Of Pennsylvania, The	Novel peptides which inhibit complement activation
US6299895B1 (en)	1997-03-24	2001-10-09	Neurotech S.A.	Device and method for treating ophthalmic diseases
AU3487697A (en)	1996-06-14	1998-01-07	Johns Hopkins University School Of Medicine, The	Use of chimeric vaccinia virus complement control proteins to inhibit complement
JPH1087700A (ja)	1996-06-17	1998-04-07	Smithkline Beecham Corp	Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
US5797898A (en)	1996-07-02	1998-08-25	Massachusetts Institute Of Technology	Microchip drug delivery devices
US6051698A (en)	1997-06-06	2000-04-18	Janjic; Nebojsa	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998046270A2 (en)	1997-04-11	1998-10-22	Advanced Medicine, Inc.	Polymeric conjugates polyvalently presenting an agent for therapy
WO1998047002A2 (en)	1997-04-11	1998-10-22	Advanced Medicine, Inc.	Polyvalent presenter combinatorial libraries and their uses
AUPO755097A0 (en)	1997-06-25	1997-07-17	University Of Queensland, The	Receptor agonist and antagonist
US6169057B1 (en)	1997-09-04	2001-01-02	The Regents Of The University Of California	Use of tryptophan and analogs as plant growth regulators
AU4648197A (en)	1997-09-17	1999-04-05	Burnham Institute, The	Peptides and peptidomimetics for inhibiting complement activation
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
JPH11197234A (ja)	1998-01-09	1999-07-27	Koken Co Ltd	眼科用コラーゲンゲル成形物
US7112327B2 (en)	1998-02-20	2006-09-26	Tanox, Inc.	Inhibition of complement activation
AU3066699A (en)	1998-03-03	1999-09-20	Johns Hopkins University, The	Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU3485999A (en)	1998-04-10	1999-11-01	Mayo Foundation For Medical Education And Research	Neo-tryptophan
US6197934B1 (en)	1998-05-22	2001-03-06	Collagenesis, Inc.	Compound delivery using rapidly dissolving collagen film
US6378526B1 (en)	1998-08-03	2002-04-30	Insite Vision, Incorporated	Methods of ophthalmic administration
US7084106B1 (en)	1999-01-19	2006-08-01	University Of Louisville Research Foundation, Inc.	Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
EP1154734B1 (en)	1999-02-12	2014-10-01	ProChon Biotech Ltd.	Injectable collagen-based system for delivery of cells
US7108982B1 (en)	1999-02-19	2006-09-19	University Of Iowa Research Foundation	Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en)	1999-02-19	2002-08-01	Hageman Gregory S.	Diagnostics and therapeutics for ocular disorders
EP1185283B1 (en)	1999-05-25	2005-09-07	King Faisal Specialist Hospital And Research Centre	Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
US6331313B1 (en)	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
GB9930659D0 (en)	1999-12-24	2000-02-16	Bio Discovery Ltd	Inhibitors of complement activation
US20050020525A1 (en)	2002-02-20	2005-01-27	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050032733A1 (en)	2001-05-18	2005-02-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7011952B2 (en)	2000-02-22	2006-03-14	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
IL151928A0 (en)	2000-03-30	2003-04-10	Whitehead Biomedical Inst	Rna sequence-specific mediators of rna interference
AU6110301A (en)	2000-04-29	2001-11-12	Univ Iowa Res Found	Diagnostics and therapeutics for macular degeneration-related disorders
US6692759B1 (en)	2000-06-28	2004-02-17	The Regents Of The University Of California	Methods for preparing and using implantable substance delivery devices
WO2002011793A1 (fr)	2000-08-08	2002-02-14	Medical Information Services, Inc.	Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US7118737B2 (en)	2000-09-08	2006-10-10	Amylin Pharmaceuticals, Inc.	Polymer-modified synthetic proteins
WO2002030985A2 (en)	2000-10-10	2002-04-18	Tanox, Inc.	Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
SI1407044T2 (en)	2000-12-01	2018-03-30	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Rna interference mediating small rna molecules
US6976982B2 (en)	2001-01-09	2005-12-20	Microchips, Inc.	Flexible microchip devices for ophthalmic and other applications
US20030175950A1 (en)	2001-05-29	2003-09-18	Mcswiggen James A.	RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050054596A1 (en)	2001-11-30	2005-03-10	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EA006746B1 (ru)	2001-11-09	2006-04-28	Айтек Фармасьютикалз	Способы лечения глазных неоваскулярных заболеваний
JP2005538033A (ja)	2001-12-04	2005-12-15	ナノスペクトラバイオサイエンセズ，インク．	過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療
DE60315949T2 (de) *	2002-01-16	2008-06-12	Biocompatibles Uk Ltd., Farnham	Polymerkonjugate
US7261876B2 (en) *	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
AUPS160602A0 (en)	2002-04-08	2002-05-16	University Of Queensland, The	Therapeutic method
WO2003105780A2 (en)	2002-06-18	2003-12-24	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
ITMI20021527A1 (it)	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en)	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
JP3976635B2 (ja)	2002-08-05	2007-09-19	久光製薬株式会社	キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
JP4614222B2 (ja)	2002-09-20	2011-01-19	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	改善された活性を有するコンプスタチン（Ｃｏｍｐｓｔａｔｉｎ）類似体
AU2003277910A1 (en)	2002-09-27	2004-04-19	Novartis Ag	Ocular gene therapy
AU2003284304B8 (en)	2002-10-21	2009-08-06	Nagler, Richard	Surface coating comprising bioactive compound
WO2004041160A2 (en)	2002-10-30	2004-05-21	University Of Kentucky Research Foundation	Methods and animal model for analyzing age-related macular degeneration
US20050048099A1 (en)	2003-01-09	2005-03-03	Allergan, Inc.	Ocular implant made by a double extrusion process
EP1594541A4 (en)	2003-02-21	2007-03-28	Rikshospitalet Radiumhospitale	METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
CN1750844B (zh)	2003-02-21	2010-09-08	健泰科生物技术公司	凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
US20050255144A1 (en)	2003-04-09	2005-11-17	Directcontact Llc	Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20070116672A1 (en)	2003-09-05	2007-05-24	Kotwal Girish J	Treatment of rheumatic diseases
CA2579635A1 (en)	2003-09-10	2005-03-17	Baxter International Inc.	Peptides that inhibit complement activation
PT1713503E (pt)	2004-02-10	2013-11-14	Nat Jewish Health	Inibição do factor b, a via alternativa do complemento e métodos relacionados
EP2578683B9 (en)	2004-02-12	2015-04-15	Archemix LLC	Aptamer therapeutics useful in the treatment of complement-related disorders
US20050244472A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244469A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Extended therapeutic effect ocular implant treatments
US20070142339A1 (en)	2004-05-10	2007-06-21	Novacea, Inc.	Prevention of arterial restenosis with active vitamin d compounds
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
JP2008512350A (ja)	2004-07-01	2008-04-24	イェールユニバーシティ	標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7947267B2 (en)	2004-10-08	2011-05-24	Potentia Pharmaceuticals, Inc.	Viral complement control proteins for eye disorders
US8043609B2 (en)	2004-10-08	2011-10-25	Potentia Pharmaceuticals, Inc.	Viral complement control proteins for eye disorders
EP1836312B1 (en)	2004-11-18	2011-10-12	Yale University	Methods and compositions for diagnosing age-related macular degenration
MX2007009565A (es)	2005-02-14	2008-03-10	Univ Iowa Res Found	Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad.
US20060257359A1 (en)	2005-02-28	2006-11-16	Cedric Francois	Modifying macrophage phenotype for treatment of disease
US20090117171A1 (en)	2005-03-11	2009-05-07	Cedric Francois	Compositions and methods for treatment of macular degeneration and related conditions
CN101325963B (zh)	2005-10-08	2016-01-27	博泰迪亚制药公司	用于眼部病症的补体抑制素和其类似物
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007047626A1 (en)	2005-10-14	2007-04-26	Alcon, Inc.	Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
BRPI0619657A2 (pt)	2005-11-04	2011-11-08	Genentech Inc	métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento
DK1960422T3 (da) *	2005-11-28	2012-08-13	Univ Pennsylvania	Meget virksomme compstatin-analoger
WO2007076437A2 (en)	2005-12-22	2007-07-05	Alcon Research, Ltd.	C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
US20070196367A1 (en)	2006-02-22	2007-08-23	Valentin Dinu	Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
AU2007232206B2 (en)	2006-03-30	2013-04-04	Drais Pharmaceuticals, Inc.	Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
US8580735B2 (en)	2007-02-05	2013-11-12	Apellis Pharmaceuticals, Inc.	Local complement inhibition for treatment of complement-mediated disorders
WO2008106186A2 (en)	2007-02-28	2008-09-04	Serina Therapeutics, Inc.	Activated polyoxazolines and compositions comprising the same
CA2691002C (en) *	2007-07-19	2016-05-10	Allexcel, Inc.	Self-assembling amphiphilic polymers as anticancer agents
WO2009015087A2 (en) *	2007-07-20	2009-01-29	Potentia Pharmaceuticals, Inc.	Compositions and methods for treatment of trauma
WO2009043027A2 (en)	2007-09-27	2009-04-02	Serina Therapeutics, Inc.	Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
RU2505311C2 (ru)	2007-10-02	2014-01-27	Потентия Фармасьютикалз, Инк.	Пролонгированная доставка аналогов компстатина из гелей
US8110651B2 (en)	2008-01-11	2012-02-07	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP2257250A2 (en)	2008-01-29	2010-12-08	Gilbert H. Kliman	Drug delivery devices, kits and methods therefor
US20110190221A1 (en)	2008-03-28	2011-08-04	Apellis Ag	Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010006282A2 (en)	2008-07-10	2010-01-14	Serina Therapeutics, Inc.	Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
EP2424557B1 (en)	2009-05-01	2017-10-25	The Trustees Of The University Of Pennsylvania	Modified compstatin with peptide backbone and c-terminal modifications
US9291622B2 (en)	2009-05-21	2016-03-22	Apellis Pharmaceuticals, Inc.	Complement assays and uses thereof
WO2011056799A1 (en) *	2009-11-05	2011-05-12	Sangart, Inc.	Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
EP2338520A1 (de) *	2009-12-21	2011-06-29	Ludwig Maximilians Universität	Konjugat mit Zielfindungsligand und dessen Verwendung
US8625635B2 (en)	2010-04-26	2014-01-07	Cleversafe, Inc.	Dispersed storage network frame protocol header
US9421240B2 (en)	2010-06-22	2016-08-23	Apellis Pharmaceuticals, Inc.	Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en)	2010-07-09	2013-12-05	Apellis Pharmaceuticals, Inc.	Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
US20140113874A1 (en)	2010-09-23	2014-04-24	The Trustees Of The University Of Pennsylvania	Modified Compstatin With Improved Stability And Binding Properties
ES2915265T3 (es)	2011-05-11	2022-06-21	Apellis Pharmaceuticals Inc	Análogos de compstatina reactivos con células, de acción prolongada o dirigidos y usos de los mismos
WO2012178083A1 (en)	2011-06-22	2012-12-27	Apellis Pharmaceuticals, Inc.	Methods of treating chronic disorders with complement inhibitors
US9630992B2 (en)	2011-09-07	2017-04-25	The Trustees Of The University Of Pennsylvania	Compstatin analogs with improved pharmacokinetic properties
US20160067357A1 (en)	2012-08-17	2016-03-10	Apellis Pharmaceuticals, Inc.	Detection of high risk drusen
US20160194359A1 (en)	2012-11-15	2016-07-07	Apellis Pharmaceuticals, Inc.	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
CN105051057B (zh)	2012-11-15	2019-11-19	阿佩利斯制药公司	细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
WO2014100407A1 (en)	2012-12-19	2014-06-26	The Regents Of The University Of California	Compstatin analogs
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
EP3023126B1 (en)	2013-07-16	2021-01-27	Beijing Mechanical Equipment Institute	Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
US9806963B2 (en)	2013-10-18	2017-10-31	Cellco Partnership	Feature activation on device
CN117503905A (zh) *	2015-10-07	2024-02-06	阿佩利斯制药有限公司	给药方案
EP3606465A4 (en) *	2017-04-07	2021-03-24	Apellis Pharmaceuticals, Inc.	DOSAGE SCHEDULES AND ASSOCIATED COMPOSITIONS AND PROCESSES

2013
- 2013-11-15 CN CN201380070393.7A patent/CN105051057B/zh active Active
- 2013-11-15 SM SM20210514T patent/SMT202100514T1/it unknown
- 2013-11-15 US US14/443,143 patent/US10035822B2/en active Active
- 2013-11-15 ES ES19205426T patent/ES2879430T3/es active Active
- 2013-11-15 CA CA2891673A patent/CA2891673A1/en active Pending
- 2013-11-15 EP EP21172151.9A patent/EP3929206A1/en not_active Withdrawn
- 2013-11-15 JP JP2015542850A patent/JP2016505527A/ja active Pending
- 2013-11-15 RS RS20211040A patent/RS62243B9/sr unknown
- 2013-11-15 PL PL13854990T patent/PL2920201T3/pl unknown
- 2013-11-15 EP EP13854990.2A patent/EP2920201B1/en active Active
- 2013-11-15 WO PCT/US2013/070417 patent/WO2014078731A2/en active Application Filing
- 2013-11-15 PT PT138549902T patent/PT2920201T/pt unknown
- 2013-11-15 DK DK13854990.2T patent/DK2920201T3/da active
- 2013-11-15 MX MX2015006154A patent/MX366404B/es active IP Right Grant
- 2013-11-15 EP EP19205426.0A patent/EP3660033B9/en active Active
- 2013-11-15 BR BR112015011244-7A patent/BR112015011244B1/pt active IP Right Grant
- 2013-11-15 LT LTEP19205426.0T patent/LT3660033T/lt unknown
- 2013-11-15 HR HRP20211342TT patent/HRP20211342T2/hr unknown
- 2013-11-15 DK DK19205426.0T patent/DK3660033T5/da active
- 2013-11-15 HU HUE19205426A patent/HUE055564T2/hu unknown
- 2013-11-15 ES ES13854990T patent/ES2780674T3/es active Active
- 2013-11-15 SI SI201331915T patent/SI3660033T1/sl unknown
- 2013-11-15 AU AU2013344462A patent/AU2013344462B2/en active Active
- 2013-11-15 PT PT192054260T patent/PT3660033T/pt unknown
- 2013-11-15 PL PL19205426T patent/PL3660033T3/pl unknown
- 2013-11-15 CN CN201911006954.2A patent/CN110882376B/zh active Active
2015
- 2015-05-15 MX MX2019007709A patent/MX2019007709A/es unknown
- 2015-05-17 IL IL238852A patent/IL238852A0/en unknown
2016
- 2016-03-23 HK HK16103411.7A patent/HK1215445A1/zh unknown
- 2016-05-09 HK HK16105236.5A patent/HK1217336A1/zh unknown
2018
- 2018-06-27 US US16/020,987 patent/US10875893B2/en active Active
- 2018-10-10 AU AU2018247243A patent/AU2018247243B2/en active Active
2019
- 2019-01-07 JP JP2019000681A patent/JP6873167B2/ja active Active
- 2019-04-14 IL IL266004A patent/IL266004A/en unknown
2020
- 2020-06-25 US US16/912,655 patent/US11292815B2/en active Active
- 2020-10-28 AU AU2020260435A patent/AU2020260435B2/en active Active
2021
- 2021-04-20 JP JP2021070898A patent/JP7093871B2/ja active Active
- 2021-09-07 CY CY20211100792T patent/CY1124474T1/el unknown
2022
- 2022-02-16 US US17/673,703 patent/US20230091471A1/en not_active Abandoned
- 2022-05-25 NO NO2022017C patent/NO2022017I1/no unknown
- 2022-05-31 LT LTPA2022010C patent/LTPA2022010I1/lt unknown
- 2022-06-03 HU HUS2200026C patent/HUS2200026I1/hu unknown
- 2022-06-03 NL NL301178C patent/NL301178I2/nl unknown
- 2022-06-08 FR FR22C1025C patent/FR22C1025I2/fr active Active
- 2022-06-20 JP JP2022098871A patent/JP7441271B2/ja active Active
2023
- 2023-02-17 AU AU2023200929A patent/AU2023200929B2/en active Active
2024
- 2024-02-16 JP JP2024022058A patent/JP2024056923A/ja active Pending

Also Published As

Publication number	Publication date
HUE055564T2 (hu)	2021-11-29
JP7441271B2 (ja)	2024-02-29
HUS2200026I1 (hu)	2022-06-28
MX366404B (es)	2019-07-08
BR112015011244A2 (pt)	2017-08-22
HRP20211342T2 (hr)	2022-08-19
HRP20211342T1 (hr)	2021-11-26
HK1217336A1 (zh)	2017-01-06
SMT202100514T1 (it)	2021-11-12
JP7093871B2 (ja)	2022-06-30
LT3660033T (lt)	2021-07-12
RU2015119165A (ru)	2017-01-10
MX2015006154A (es)	2015-12-01
US10875893B2 (en)	2020-12-29
EP3660033B1 (en)	2021-06-09
FR22C1025I1 (fr)	2022-07-22
IL238852A0 (en)	2015-06-30
EP3660033A1 (en)	2020-06-03
NO2022017I1 (no)	2022-05-25
HK1215445A1 (zh)	2016-08-26
CY1124474T1 (el)	2022-07-22
AU2020260435A1 (en)	2020-11-26
US20230091471A1 (en)	2023-03-23
EP3929206A1 (en)	2021-12-29
JP6873167B2 (ja)	2021-05-19
PL3660033T3 (pl)	2021-12-06
AU2013344462A1 (en)	2015-06-04
AU2023200929A1 (en)	2023-03-23
EP2920201A2 (en)	2015-09-23
DK2920201T3 (da)	2020-04-14
IL266004A (en)	2019-06-30
JP2019070011A (ja)	2019-05-09
US11292815B2 (en)	2022-04-05
PT2920201T (pt)	2020-04-03
BR112015011244B1 (pt)	2022-08-09
US20210032289A1 (en)	2021-02-04
WO2014078731A2 (en)	2014-05-22
AU2018247243B2 (en)	2020-08-06
JP2016505527A (ja)	2016-02-25
DK3660033T3 (da)	2021-07-05
CN110882376A (zh)	2020-03-17
JP2021107441A (ja)	2021-07-29
BR112015011244A8 (pt)	2018-01-23
CN105051057A (zh)	2015-11-11
AU2018247243A1 (en)	2018-11-01
AU2023200929B2 (en)	2024-12-12
RS62243B1 (sr)	2021-09-30
JP2022120193A (ja)	2022-08-17
CA2891673A1 (en)	2014-05-22
PL2920201T3 (pl)	2020-10-05
NL301178I2 (nl)	2024-04-25
AU2013344462B2 (en)	2018-07-12
SI3660033T1 (sl)	2021-09-30
PT3660033T (pt)	2021-07-06
DK3660033T5 (da)	2022-06-27
EP2920201A4 (en)	2016-10-12
JP2024056923A (ja)	2024-04-23
MX2019007709A (es)	2019-09-06
US20190194254A1 (en)	2019-06-27
US20160215020A1 (en)	2016-07-28
US10035822B2 (en)	2018-07-31
LTPA2022010I1 (hu)	2022-06-27
EP3660033B9 (en)	2022-06-22
EP2920201B1 (en)	2020-01-08
RU2705215C2 (ru)	2019-11-06
AU2020260435B2 (en)	2022-11-17
CN110882376B (zh)	2023-10-20
CN105051057B (zh)	2019-11-19
ES2780674T3 (es)	2020-08-26
WO2014078731A3 (en)	2014-07-31
RS62243B9 (sr)	2022-11-30
ES2879430T3 (es)	2021-11-22

Publication	Publication Date	Title
FR22C1025I2 (fr)	2023-11-24	Analogues de la compstatine à longue durée d'action et compositions et méthodes associées
CY2022015I1 (el)	2023-01-05	Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι
EP2707384A4 (en)	2014-11-19	CELL REACTIVE, LONG-TERM OR TARGETED COMPSTATIN ANALOGUES AND USES THEREOF
EP3636148C0 (en)	2023-11-29	PORTABLE HEART MONITOR
EP2694095A4 (en)	2014-12-24	COMPOSITIONS COMPRISING GLUCAGON ANALOGUES AND METHODS OF MAKING AND USING THE SAME
BR112015002512A2 (pt)	2018-05-15	limpador interdental
BR112014015681A2 (pt)	2019-09-24	análogos de glucagon
EP2787837A4 (en)	2015-05-20	COMMONLY DECOMPOSED STABILIZER COMPOSITION
EP2696884A4 (en)	2014-12-24	PEPTIDE ANALOGUE WITH LONG TERM EFFECT
EP2776162A4 (en)	2015-06-03	MOISTURE-HARDENABLE ORGANOPOLYSILOXANE COMPOSITION
BR112013024076A2 (pt)	2016-12-06	análogos de glucagon
EP2914620A4 (en)	2016-05-25	LONG-ACTING UNIQUE INSULIN ANALOG
BR112013008864A2 (pt)	2016-06-28	análogos d ciclosporina
FR2970177B1 (fr)	2013-08-02	Composition huileuse demaquillante
EP2714975A4 (en)	2014-11-12	ELASTIC FABRIC
EP2676595A4 (en)	2014-03-12	ENDOSCOPADAPTER AND ENDOSCOPE
EP2931042A4 (en)	2016-06-01	ANTHRACYCLINFORMULIERUNGEN
BR302012001298S1 (pt)	2014-08-19	Configuração aplicada edm equipamento médico
EP2680871A4 (en)	2015-04-22	SYMBOLS HORMONE ANALOGUE, COMPOSITIONS THEREOF AND USES THEREOF
DK2672817T3 (da)	2017-11-20	Forbedrede insekticide formuleringer
BR112013013550A2 (pt)	2016-10-11	membro de limpeza de material à base de elastômero (s) sobrerreticulado
ES1076265Y (es)	2012-05-23	Estructura de proteccion flexible mejorada
EP2922817A4 (en)	2016-06-22	OMEGA-3 Analogs
EP2760820A4 (en)	2015-04-29	SPHINGOSINANALOGA, COMPOSITIONS AND METHOD THEREFOR
CL2014001638A1 (es)	2014-11-14	Analogos de glucagon